Phase 2 N=34 Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana in Daily Marijuana Smokers
Pain Threshold · Mood
Primary: Pain Tolerance — 6.1; 2.8; 4.9; 1.5 seconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=16 Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects
Hepatitis C, Chronic
Primary: Number of Participant Achieving Rapid Virological Response (RVR) at Day 28, Nominal Analysis — 3; 3; 8; 1 Participants
Phase 2 N=15 Therapeutic Cocaine Vaccine: Human Laboratory Study
Cocaine Dependence
Primary: Cocaine Intoxication — 59; 51; 45; 44 units on a scale
Phase 2 N=74 A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)
Carcinoma, Renal Cell
Primary: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Criteria Version 1.0 — 13.5; 13.5 Percentage of participants
Phase 2 N=25 Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality
Chronic Pancreatitis · Insulin Resistance · Normal or Mildly Abnormal Stool Fat Levels
Primary: Glucose Tolerance at 24 Weeks — 2; 4; 3; 4 Participants
Phase 2 N=21 Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia
B-Cell Prolymphocytic Leukemia · Chronic Lymphocytic Leukemia · Prolymphocytic Leukemia
Primary: Overall Survival — 15 Participants
Phase 2 N=13 Nuedexta for the Treatment of Adults With Autism
Autism
Primary: Change in Maladaptive Behaviors — -6.62; -1.08 units on a scale
Phase 2 N=205 Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 70.6; 100.0; 93.9; 80.6 percentage of participants
Phase 2 N=309 Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap
Leiomyoma
Primary: Percentage of Subjects With Amenorrhea, Defined as no Scheduled or Unscheduled Bleeding/Spotting After the End of the Initial Bleeding Episode Until End of Treatment…
Phase 2 N=9 Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study
Epithelial Ovarian Cancer
Primary: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) — 7; 2 participants
Phase 2 N=30 Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Progression-free for at Least 6 Months Without Non-protocol Therapy From Study Entry — 20 percentage of participants
Phase 2 N=32 A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor
Hereditary Angioedema
Primary: Number of HAE Attacks — 2.74; 4.36; 7.18 attacks
Phase 2 N=20 Role of Everolimus in Highly Sensitized Patients
Highly-sensitized Kidney Transplant Recipients
Primary: The Number of Polyoma BK Viremia Patients — 5 Participants
Phase 2 N=682 A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease
Alzheimer's Disease
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 24 — 1.2; 0.5; -0.4 Score on scale — p=0.279
Phase 2 N=55 Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Surgical Procedures
Primary: Change From Baseline to Peak in Cerebrospinal Fluid (CSF) S100 Beta Within 48 Hours Following Descending Thoracic Aorta/Thoracoabdominal Aortic Aneurysm (DTA/TAAA)…